To report an adverse event or product quality issue, please email us at reportnow@argenx.com or call us at 1-833-274-9411.
©2026 argenx | Disclaimer | Privacy Policy | Regulations | U.S. Supplemental Privacy Notice
The Power of Team
We are an immunology innovation company, co-creating entrepreneurial science. We’re seeking a new approach to science, one that challenges conventions and expands possibilites for patients. We innovate with more impact because we bring academic discovery, clinical insight, and patient experience together. We welcome those inspired to pursue uncharted pathways. Those emboldened to remove barriers, expand possibilities, and accelerate immunology innovation.
We are argenx and we co-create bold pathways to transform yesterday's unthinkable immunology science into the medicines patients need today.
Story of the Argonauts
The name “argenx” comes from Greek lore. A tale that celebrated the collective power of a team over that of a single hero. In a small boat, the Argonauts sailed the ocean in search of the golden fleece. It was a seemingly impossible task, but through the efforts of the team—and the unique contributions of each individual—the Argonauts achieved the unthinkable.
We too are pursuing the seemingly unattainable. Like the Argonauts, our team is successfully navigating uncharted pathways through the power of partnership and co-creation.
We are helping engineer life-changing medicines for patients that need them.
Our Timeline
2008
Founded
Our first moment of co-creation: three biotech entrepreneurs and scientists with the goal of accelerating innovation in immunology founded argenx. The name is inspired by the mythological Argonauts, symbols of teamwork and collective achievement.
IPO on Euronext Brussels
Completed our initial public offering on Euronext Brussels (ticker ARGX).
2014
2017
Listing on NASDAQ Global Select Market
Expanded public presence by listing on the NASDAQ Global Select Market in the United States.
First FDA Approval
Received landmark FDA approval for our first commercial drug—VYVGART (efgartigimod alfa-fcab). An FcRn blocker, it was designed to treat adults with anti-AChR Ab positive generalized myasthenia gravis (gMG).
2021
2022
VYVGART Hytrulo Approved
Received EU Commission marketing authorization and FDA approval for VYVGART Hytrulo, a subcutaneous formulation offering a new delivery option.
Expanding Possibilities
Recorded global product sales of $2.2 billion while expanding the VYVGART franchise into new indications and geographies, including the first global approval of VYVGART for primary immune thrombocytopenia (ITP) in Japan and US FDA approval of VYVGART Hytrulo for adults with chronic inflammatory demyelinating polyneuropathy (CIDP).
2024
2025—Present
Full Pursuit of Innovation
Continued growth as a commercial-stage immunology leader, expanding the reach of VYVGART to more patients globally through FDA approval for all gMG serotypes and a prefilled syringe (PFS) option for self-injection, while advancing a broad pipeline in support of our ambition to be a leading multi-asset immunology company.
Our Cultural Pillars
These foundational principles are what guide our culture. Every day they steer both our business relationships and partnerships in our labs, offices, and beyond.
Innovation
Our core mission is to challenge scientific conventions so we can bring better treatments to patients with severe autoimmune diseases.
Co-Creation
As individuals we can do a job, but together we have the power to expand possibilities.
Empowerment
Our teams are unbound, free to move the way agile minds work to pursue new approaches to science.
Excellence
We want to create science that serves all, and that means accelerating innovation, making it safer, and having a greater impact on lives.
- 1
- 2
Innovation
Our core mission is to challenge scientific conventions so we can bring better treatments to patients with severe autoimmune diseases.
Co-Creation
As individuals we can do a job, but together we have the power to expand possibilities.
Empowerment
Our teams are unbound, free to move the way agile minds work to pursue new approaches to science.
Excellence
We want to create science that serves all, and that means accelerating innovation, making it safer, and having a greater impact on lives.
- Innovation
- Co-Creation
- Empowerment
- Excellence
Our Leaders
Get to know the people guiding us in a new approach to science that is moving immunology faster than thought possible.
Explore More
At argenx, every piece of the innovation story connects. See where it leads next.
Who We Are
We build on each other’s passion to achieve a shared purpose.
Grants
Funding research, education, and initiatives that raise the standard of care.
Ethics and Responsibility
Explore how we’re doing things the right way and staying true to our core values.
